Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.

Intellia Therapeutics Inc
Start price
€33.50
13.04.23 / 50%
Target price
€59.72
13.04.24
Performance (%)
-29.85%
End price
€23.50
14.04.24
Summary
This prediction ended on 14.04.24 with a price of €23.50. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.85%. Canaccord_Genuity_Gr has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Intellia Therapeutics Inc 0.049% 0.049% -40.105%
iShares Core DAX® 0.961% -2.210% 12.839%
iShares Nasdaq 100 2.626% -1.918% 38.498%
iShares Nikkei 225® 0.217% -7.216% 19.425%
iShares S&P 500 1.540% -1.858% 27.801%

Comments by Canaccord_Genuity_Gr for this prediction

In the thread Intellia Therapeutics Inc diskutieren
Prediction Buy
Perf. (%) -29.85%
Target price 59.723
Change
Ends at 13.04.24

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat

Canaccord Genuity Group Inc. 
0
Report Share
13.04.23
In the thread Trading Intellia Therapeutics Inc
Prediction Buy
Perf. (%) -29.85%
Target price 59.723
Change
Ends at 13.04.24

Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten

Canaccord Genuity Group Inc. 
0
Report Share
14.04.24